DK1708679T3 - Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin - Google Patents

Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin

Info

Publication number
DK1708679T3
DK1708679T3 DK04798662T DK04798662T DK1708679T3 DK 1708679 T3 DK1708679 T3 DK 1708679T3 DK 04798662 T DK04798662 T DK 04798662T DK 04798662 T DK04798662 T DK 04798662T DK 1708679 T3 DK1708679 T3 DK 1708679T3
Authority
DK
Denmark
Prior art keywords
hydrofluoroalkane
spray formulation
pharmaceutical spray
acylated cyclodextrin
acylated
Prior art date
Application number
DK04798662T
Other languages
English (en)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1708679T3 publication Critical patent/DK1708679T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
DK04798662T 2003-11-26 2004-11-24 Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin DK1708679T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds
PCT/GB2004/004957 WO2005053637A2 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin

Publications (1)

Publication Number Publication Date
DK1708679T3 true DK1708679T3 (da) 2009-02-16

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04798662T DK1708679T3 (da) 2003-11-26 2004-11-24 Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin

Country Status (24)

Country Link
US (1) US20070104652A1 (da)
EP (1) EP1708679B1 (da)
JP (1) JP4950666B2 (da)
KR (1) KR20060118509A (da)
CN (1) CN100592908C (da)
AT (1) ATE413868T1 (da)
AU (1) AU2004294775B2 (da)
BR (1) BRPI0416992A (da)
CA (1) CA2546441C (da)
CY (1) CY1108753T1 (da)
DE (1) DE602004017783D1 (da)
DK (1) DK1708679T3 (da)
ES (1) ES2314469T3 (da)
HK (1) HK1108390A1 (da)
IL (1) IL175659A (da)
MX (1) MXPA06005643A (da)
NO (1) NO20062969L (da)
NZ (1) NZ547355A (da)
PL (1) PL1708679T3 (da)
PT (1) PT1708679E (da)
SE (1) SE0303179D0 (da)
SI (1) SI1708679T1 (da)
WO (1) WO2005053637A2 (da)
ZA (1) ZA200604330B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
KR20240127331A (ko) * 2021-12-28 2024-08-22 린텍 가부시키가이샤 실리콘계 점착제, 점착 시트 및 양면 점착 시트

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW249226B (da) * 1990-04-04 1995-06-11 Aderk Ueno Kk
DE69103503T2 (de) * 1990-09-28 1995-01-05 Mercian Corp Adriamycinderivate.
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
AU2004294775A1 (en) 2005-06-16
NO20062969L (no) 2006-08-25
AU2004294775B2 (en) 2007-12-20
KR20060118509A (ko) 2006-11-23
HK1108390A1 (en) 2008-05-09
WO2005053637A2 (en) 2005-06-16
IL175659A (en) 2010-02-17
DE602004017783D1 (de) 2008-12-24
US20070104652A1 (en) 2007-05-10
JP4950666B2 (ja) 2012-06-13
PL1708679T3 (pl) 2009-04-30
PT1708679E (pt) 2008-12-29
CY1108753T1 (el) 2014-04-09
SI1708679T1 (sl) 2009-04-30
NZ547355A (en) 2009-05-31
WO2005053637A3 (en) 2007-06-28
BRPI0416992A (pt) 2007-02-06
SE0303179D0 (sv) 2003-11-26
ZA200604330B (en) 2007-11-28
MXPA06005643A (es) 2006-08-17
CN101087600A (zh) 2007-12-12
EP1708679A2 (en) 2006-10-11
ES2314469T3 (es) 2009-03-16
IL175659A0 (en) 2006-09-05
CN100592908C (zh) 2010-03-03
CA2546441C (en) 2011-11-22
ATE413868T1 (de) 2008-11-15
JP2007515401A (ja) 2007-06-14
EP1708679B1 (en) 2008-11-12
CA2546441A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
HRP20060240T3 (en) Intranasal formulation of rotigotine
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
CY2016024I2 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
BRPI0509827A (pt) nanopartìculas pegiladas para transporte de moléculas biologicamente ativas, composição farmacêutica, liofilizato constituindo nanopartìculas pegiladas e processo de preparação de nanopartìculas pegiladas
ATE496064T1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
DK1319183T3 (da) Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
BRPI0407583A (pt) solução oftálmica lìmpida e estável
CY1110664T1 (el) Ενδορινικες συνθεσετς
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
AU5218001A (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
HK1057336A1 (en) Pharmaceutical solutions of modafinil compounds
AR058141A1 (es) Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
NO20076120L (no) Stabile nanopartikkelformuleringer
DK1708679T3 (da) Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
DE50308344D1 (de) Cyclodextrine als suspensionsstabilisatoren in druckverflüssigten treibmitteln
AU2006272424A8 (en) Homogemcitabines
DK1200088T3 (da) Sammensætning indeholdende paracetamol og drotaverin
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
WO2004111088A3 (en) Angiogenic factor and inhibitors thereof